Next, to determine whether GRP78 targeting has a therapeutic effect in RCC and whether GRP78 inhibition makes RCC cells more vulnerable to anti-VEGF-targeted therapy, we developed tetracycline-inducible shGRP78-expressing Caki-1 cells and established subcutaneous xenografts using these cells in nude mice (Figure 6C). The gene discussed is HSPA5; the disease is renal cell carcinoma.